EVMN logo

EVMNEvommune Inc

$19.92
$0.77
(3.72%)
Today
Closed $19.92
$0.35
(1.76%)
After Hours
Updated: 06:53 PM EDT
Mkt Cap$745.22M
Vol417,444.00
News
all
press releases
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
Evommune, Inc. (NYSE: EVMN) (Evommune or the Company), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced...
Business Wire
News Placeholder
More News
News Placeholder
Wall Street Zen Downgrades Evommune (NYSE:EVMN) to Sell
Wall Street Zen downgraded Evommune from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat
News Placeholder
Evommune (NYSE:EVMN) Coverage Initiated by Analysts at Stifel Nicolaus
Stifel Nicolaus began coverage on shares of Evommune in a report on Friday. They set a "buy" rating and a $54.00 target price on the stock...
MarketBeat
News Placeholder
Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Buy" from Brokerages
Evommune, Inc. (NYSE:EVMN - Get Free Report) has been given an average rating of "Buy" by the thirteen brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and...
MarketBeat
News Placeholder
Evommune, Inc.'s (NYSE:EVMN) Lock-Up Period To Expire on May 5th
Evommune's (NYSE:EVMN - Get Free Report) lock-up period will end on Tuesday, May 5th. Evommune had issued 9,375,000 shares in its initial public offering on November 6th. The total size of the...
MarketBeat
News Placeholder
Evommune (NYSE:EVMN) Stock Price Down 7.2% - Here's Why
Evommune (NYSE:EVMN) Stock Price Down 7.2% - What's Next...
MarketBeat
News Placeholder
Evommune (NYSE:EVMN) Earns Outperform Rating from Royal Bank Of Canada
Royal Bank Of Canada reissued an "outperform" rating and set a $48.00 target price on shares of Evommune in a report on Friday...
MarketBeat
News Placeholder
Evommune (NYSE:EVMN) Shares Up 4.7% - Here's What Happened
Evommune (NYSE:EVMN) Shares Up 4.7% - Time to Buy...
MarketBeat
News Placeholder
Oppenheimer Initiates Coverage on Evommune (NYSE:EVMN)
Oppenheimer assumed coverage on shares of Evommune in a research note on Tuesday. They issued an "outperform" rating and a $50.00 target price on the stock...
MarketBeat
News Placeholder
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
Evommune, Inc. (NYSE: EVMN) (Evommune or the Company), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced...
Business Wire
<
1
2
...
>

Advertisement|Remove ads.